Blog
Qizheng Tibetan Medicine (002287) has been selected as a Best Practice Case in Corporate Governance for 2023 by the China Association of Listed Companies.
Release time:
2023-11-02 09:56
Recently, the results of the “2023 Best Practice Cases in Corporate Governance by the China Association for Listed Companies” were announced. Through a rigorous selection and review process, Qizheng Tibetan Medicine stood out from over 5,000 A-share listed companies and was selected as a best practice case, with its case study included in the “China Listed Companies Governance Report.”
It is reported that this selection event is organized by the China Association of Listed Companies. Its purpose is to leverage the leading and exemplary role of best practices, guiding listed companies to benchmark against each other, learn from one another, and further enhance their corporate governance standards. The report of the 20th National Congress of the Communist Party of China outlined important tasks such as “improving the modern enterprise system with Chinese characteristics” and “accelerating the building of world-class enterprises.” World-class enterprises encompass a rich array of attributes, among which modernized governance is a key element.
Qizheng Tibetan Medicine adheres to the corporate governance philosophy of “strategic leadership, professional empowerment, and standardized practices for long-term success.” It regards safeguarding the interests of investors—especially those of small and medium-sized investors—as a key guiding principle and primary focus of its work. The company is strict with itself, continuously improving its corporate governance structure and strengthening its internal control system. It has undertaken distinctive and highly effective practices in areas such as board governance, information disclosure, and investor relations management.
The company’s board of directors makes decisions in a scientifically independent manner, with external directors accounting for over 70% of the total board members; independent directors comprise more than one-third of all directors. From 2015 to 2021, the company received an A-level rating for information disclosure assessment from the Shenzhen Stock Exchange for seven consecutive years. The company has established a diversified investor relations platform, including a dedicated investor relations hotline, an investor relations email address, an official investor relations public account, and an investor relations mini-program, providing timely responses to various inquiries from investors. On the “Interactive Easy” platform, the response rate is 100%.
Since its IPO in 2009, the company has distributed cash dividends 14 times, with a total cumulative dividend amount of 2.322 billion yuan and a dividend payout ratio of 50.62%.
Ms. Feng Ping, Vice President and Board Secretary of Qizheng Tibetan Medicine, stated: In the future, we will continue to enhance our corporate governance standards, operate in compliance with the law, and uphold our core values of “doing good and benefiting others, pursuing integrity and righteous business practices, and respecting heaven and loving people.” While achieving sustainable and healthy development, we will comprehensively safeguard the legitimate rights and interests of small and medium-sized investors.
Recommended News
2026-05-25
Copyright Qizheng Tibetan Medicine Co., Ltd. All rights reserved. ICP Filing Number:
Internet drug information service qualification certificate number:（藏） Non-Commercial - 2018-0004 SEO